This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

World Blood Banking Market Emerging Opportunities Scrutinised In New In-Demand VPG Study Available At Marketpublishers.com

Over the coming five-year period, transfusion diagnostics practice is bound to be revolutionized owing to a combination of factors. These resultant market changes will offer bright opportunities for new reagent systems and instruments, as well as for a slew of auxiliary products.

New study “Competing in the Global Blood Banking Market” created by Venture Planning Group (VPG) is designed to identify and evaluate emerging opportunities in the global blood banking market during the next five years.

The report explores future marketing and technological trends in the key geographies – the US, Europe (France, Germany, Italy, Spain, and the UK) and Japan. It provides sales and market share estimates for major reagent and instrument suppliers by country and product; test volume and sales forecasts for over 40 transfusion diagnostic tests (including NAT) by country and market segment; instrument placements and installed base by manufacturer and model; comparison of major automated and semi-automated analyzers. The profiles of the top competitors and emerging market entrants developing innovative technologies and products, along with reviews of specific product and marketing opportunities expected to face suppliers during the next decade are also covered.

Companies discussed include Abbott, Beckman Coulter/Danaher, Becton Dickinson, Biokit, BioMerieux, Bio-Rad, Diagast, DiaSorin, Fujirebio, Gen-Probe, Grifols, Immucor, Innogenetics, Ortho-Clinical Diagnostics, Orchid CellMark, Novartis Diagnostics, Proteome Sciences, Roche, Siemens, and Tecan.

Report Details:

Title: Competing in the Global Blood Banking Market

Published: February, 2013

Pages: 800

Price: US$ 32,500.00

http://marketpublishers.com/report/in_vitro_diagnostics/blood_banking/competing-in-global-blood-banking-market.html

More Diagnostics & Diseases Market Studies by VPG Include:

More new studies by VPG can be found at http://marketpublishers.com/members/vpg/info.html

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,776.91 +93.33 0.53%
S&P 500 2,081.34 +12.58 0.61%
NASDAQ 4,997.4590 +5.5190 0.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs